{"entity":{"id":"ghsg","kind":"company","name":"German Hodgkin Study Group","aka":["GHSG","Deutsche Hodgkin Studiengruppe"],"tldr":"The Cologne-based group whose HD trials, from BEACOPP to BrECADD in HD21, have set the standard for treating Hodgkin lymphoma for four decades.","summary":"Founded in 1978 by Volker Diehl and based at the University Hospital of Cologne, the GHSG has enrolled tens of thousands of patients in sequential HD trials that defined stage-adapted therapy. Its work produced the escalated BEACOPP regimen, showed PET-guided de-escalation is safe (HD16, HD18), and in HD21 showed brentuximab-based BrECADD is less toxic and at least as effective as BEACOPP in advanced disease. The group runs a central review panel for pathology and imaging and long-term survivorship studies of second cancers and cardiac toxicity. It sits within the Department I of Internal Medicine at Cologne.","asOf":"2026-09-09","links":[{"label":"GHSG","url":"https://www.ghsg.org"}],"tags":["cooperative-group"],"related":["brentuximab-vedotin","nivolumab"],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["fdg-pet","adc","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["german-lymphoma-alliance"],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":["hd21"],"people":["michael-hallek"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["HD trial series (HD1-HD21)","PET-guided treatment adaptation","HD21 (BrECADD)","Survivorship and late-effects research"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Cologne","country":"DE","companyType":"cooperative-group","website":"https://www.ghsg.org","founded":1978,"investors":[],"funding":[]},"route":"/companies/ghsg/","neighbours":{"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"}],"company":[{"id":"german-lymphoma-alliance","kind":"company","name":"German Lymphoma Alliance","route":"/companies/german-lymphoma-alliance/"}],"institution":[{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/"}],"trial":[{"id":"hd10","kind":"trial","name":"GHSG HD10","route":"/trials/hd10/"},{"id":"hd16","kind":"trial","name":"GHSG HD16","route":"/trials/hd16/"},{"id":"hd18","kind":"trial","name":"GHSG HD18","route":"/trials/hd18/"},{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/"}],"person":[{"id":"andreas-engert","kind":"person","name":"Andreas Engert","route":"/people/andreas-engert/"},{"id":"michael-hallek","kind":"person","name":"Michael Hallek","route":"/people/michael-hallek/"},{"id":"peter-borchmann","kind":"person","name":"Peter Borchmann","route":"/people/peter-borchmann/"}],"paper":[{"id":"paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020","kind":"paper","name":"Long-term follow-up of nodular lymphocyte-predominant Hodgkin lymphoma treated in the GHSG HD7 to HD15 trials","route":"/key-papers/paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020/"},{"id":"paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017","kind":"paper","name":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/"},{"id":"paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019","kind":"paper","name":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019/"}]}}